Prospects of elafibranor in treating alcohol-associated liver diseases

World Journal of Gastroenterology, Год журнала: 2024, Номер 31(2)

Опубликована: Дек. 18, 2024

Alcohol-related liver disease (ALD), which is induced by excessive alcohol consumption, a leading cause of liver-related morbidity and mortality. ALD patients exhibit spectrum injuries, including hepatic steatosis, inflammation, fibrosis, similar to symptoms nonalcohol-associated diseases such as primary biliary cholangitis, metabolic dysfunction-associated steatotic disease, nonalcoholic steatohepatitis. Elafibranor has been approved for the treatment cholangitis shown improve in both animal models vitro cell However, efficacy elafibranor treating remains unclear. In this article, we comment on recent publication Koizumi et al that evaluated effects fibrosis gut barrier function an mouse model. Their findings indicate potential treatment, but further experimental investigations clinical trials are warranted.

Язык: Английский

---

Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease

World Journal of Gastroenterology, Год журнала: 2024, Номер 31(3)

Опубликована: Дек. 17, 2024

This article discusses the recent study written by Koizumi et al. Alcohol-associated liver disease (ALD) is a major cause of liver-related morbidity and mortality, which driven complex mechanisms, including lipid accumulation, apoptosis, inflammatory responses exacerbated gut barrier dysfunction. The explored therapeutic potential elafibranor, dual peroxisome proliferator-activated receptor alpha/delta agonist. In clinical trials, elafibranor has shown promise for treatment other conditions; however, its effects on ALD remain unclear. authors' findings indicate that significantly reduced fibrosis enhanced integrity in patients with ALD. These positive are mediated through multiple pathways. Elafibranor promotes metabolism, reduces oxidative stress, inhibits restoring function. Specifically, it improves hepatocyte function enhancing autophagic antioxidant capacity, mitigates inflammation suppressing lipopolysaccharide/toll-like 4/nuclear factor kappa B signaling pathway. promising applications. addition, highlights elafibranor's as agent diseases, particularly underscores importance understanding mechanistic pathways underlying suggests directions future research aimed at elucidating benefits limitations elafibranor.

Язык: Английский

---

Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model

World Journal of Gastroenterology, Год журнала: 2024, Номер 31(4)

Опубликована: Дек. 30, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent pathology in need of novel pharmacological treatments to complement lifestyle-based interventions. Nuclear receptor agonists have been under scrutiny as potential targets and today, resmetirom, thyroid hormone b agonist, the only approved agent. The dual PPAR α δ agonist elafibranor has also undergone extensive clinical testing, which reached phase III trial but failed demonstrate beneficial effect on MASLD. As alcohol-associated MASLD can be interconnected, whether might affective against caused by alcohol consumption worth investigating. Writing recently World Journal Gastroenterology, Koizumi et al reported using mouse model found that hepatic steatosis, fibrosis, hepatocyte apoptosis were alleviated administration elafibranor. Although preclinical nature, these data support action alcohol-induced MASLD, warranting testing this molecule patients with consumption.

Язык: Английский

---